MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients
The trial is evaluating its lead clinical candidate, ateganosine (THIO), sequenced with Regeneron Pharmaceutical Inc's (NASDAQ:REGN) immune checkpoint inhibitor (CPI) cemiplimab (Libtayo) for advanced non-small cell lung cancer (NSCLC) who are resistant to immune therapy and chemotherapy.
As of May 15, third line (3L) data showed median overall survival (OS) of 17.8 months for the 22 NSCLC patients who received at least one dose of ateganosine (the intent-to-treat population) in parts A and B of the trial. The updated analysis demonstrates a 95% confidence interval (CI) lower bound of 12.5 months and a 99% CI lower bound of 10.8 months.The treatment has been generally well-tolerated to date in this heavily pretreated population.
At the data cutoff, the patient with the longest survival in the trial had completed 32 cycles of therapy and had 24.3 months survival.
Studies of standard-of-care (SOC) chemotherapy treatments for NSCLC in a similar setting have shown OS of 5 to 6 months.
'This new benchmark of 17.8 months median OS is nearly triple the recognized SOC data for third-line NSCLC found in the medical literature. We believe this is a substantial indicator of the potential ateganosine has to shift the NSCLC treatment landscape,' said MAIA Chairman and CEO Vlad Vitoc.
MAIA's multiple potential regulatory pathways for ateganosine could provide accelerated FDA approval and robust exclusivity in NSCLC, with a potential FDA decision as early as next year.
The company announced a new partial response (PR) was identified in a patient after 20 months of treatment. A partial response is defined as a decrease in tumor size of at least 30%.
'The patient remained on treatment and we observed stable disease for more than twenty months before the partial response was identified, highlighting the efficacy, safety and low toxicity of the treatment,' Vitoc added.
Price Action: MAIA stock is up 11.7% at $1.97 at the last check on Thursday.
Read Next:Photo via Shutterstock
UNLOCKED: 5 NEW TRADES EVERY WEEK. Click now to get top trade ideas daily, plus unlimited access to cutting-edge tools and strategies to gain an edge in the markets.
Get the latest stock analysis from Benzinga?
This article MAIA Biotechnology's Experimental Cancer Drug Shows Tripled Survival Vs. Standard Chemotherapy In Pretreated Lung Cancer Patients originally appeared on Benzinga.com
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Business News
an hour ago
- Time Business News
The Science Behind Recovery in Accredited Addiction Treatment Centers
Accredited addiction treatment centers function within a rigorously structured framework that upholds both safety and efficacy. Accreditation is granted by recognized bodies such as CARF (Commission on Accreditation of Rehabilitation Facilities) or The Joint Commission, which ensures adherence to strict clinical standards. These institutions are required to follow evidence-informed protocols, maintain licensed medical staff, and continuously evaluate treatment outcomes. This foundational integrity not only enhances credibility but ensures that clients receive care rooted in scientific rigor. Accreditation acts as a protective mechanism—safeguarding the quality of intervention throughout a patient's journey toward sobriety. When taking medications that influence the brain and body, it's essential to know how long their effects may linger. One such medication, used to manage opioid dependence, remains detectable in the body for varying durations depending on several factors. How Long does suboxone stay in your system depends on the dosage, metabolism, liver function, and frequency of use. On average, its primary component, buprenorphine, can be detected in urine for up to 7–10 days. However, traces may persist longer in hair or blood. Awareness of these timelines can aid in treatment planning and ensure safe, informed recovery decisions. Addiction is not a moral failing; it is a neurological hijacking. Chronic substance use fundamentally rewires the brain, particularly areas responsible for reward, impulse control, and emotional regulation. Dopaminergic surges create a feedback loop that distorts natural reward pathways, often rendering daily pleasures obsolete. However, the brain retains an extraordinary ability—neuroplasticity. During recovery, with sustained abstinence and therapeutic intervention, neural circuits begin to recalibrate. This slow but measurable restoration underpins the physiological basis of long-term recovery. Accredited centers harness this science to structure timelines and therapies that support biological healing. The arsenal of treatment strategies deployed in accredited centers is backed by empirical research and clinical validation. Cognitive Behavioral Therapy (CBT), for instance, is proven to restructure maladaptive thought patterns that often fuel substance abuse. Medication-Assisted Treatment (MAT), using FDA-approved drugs like buprenorphine or naltrexone, addresses both withdrawal symptoms and cravings with biochemical precision. More recently, modalities such as Eye Movement Desensitization and Reprocessing (EMDR) and biofeedback have emerged with strong neuroscientific endorsements. The underlying principle across these therapies is consistency with data—interventions are only used if they withstand rigorous peer-reviewed scrutiny. Many individuals grappling with addiction concurrently suffer from psychiatric conditions such as depression, PTSD, or bipolar disorder. This phenomenon, known as dual diagnosis, complicates recovery if left unaddressed. Accredited centers prioritize integrated care models that simultaneously treat substance use and mental health disorders. Clinical staff are trained to identify overlapping symptoms and deploy multidisciplinary approaches, combining psychiatry, psychotherapy, and pharmacology. The science is clear: treating both conditions in tandem leads to significantly higher recovery rates, preventing relapse born from untreated psychological triggers. Recovery is not a solitary expedition—it's a communal journey. Group therapy sessions, peer support communities like 12-Step programs, and structured social interactions offer critical emotional scaffolding. Neuroscience confirms that oxytocin release during empathetic social encounters can modulate stress responses, aiding in relapse prevention. Family therapy also plays a vital role by reconstructing fractured relational ecosystems and improving communication patterns. These psychosocial mechanisms, when embedded in a scientific treatment plan, amplify resilience and elevate recovery prospects. Data is the backbone of modern addiction treatment. Accredited centers employ advanced outcome-tracking tools to personalize and recalibrate treatment plans. From biometric monitoring to standardized psychological assessments, progress is meticulously documented. Longitudinal studies, often conducted in collaboration with academic institutions, inform best practices and fuel innovation. These research initiatives uncover new biomarkers, refine predictive models for relapse, and explore genetic predispositions to addiction—transforming treatment from reactive to proactive. Accredited addiction treatment centers represent the confluence of empirical science and human empathy. Their methodologies are steeped in neurobiological understanding, evidence-based therapies, and continuous innovation. Yet, beyond the science lies a fundamental ethos—compassion. By aligning clinical excellence with individualized care, these centers don't just treat addiction; they restore dignity, purpose, and the innate human capacity for transformation. TIME BUSINESS NEWS
Yahoo
2 hours ago
- Yahoo
The Lovesac Company's (NASDAQ:LOVE) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
Lovesac (NASDAQ:LOVE) has had a great run on the share market with its stock up by a significant 34% over the last three months. But the company's key financial indicators appear to be differing across the board and that makes us question whether or not the company's current share price momentum can be maintained. Specifically, we decided to study Lovesac's ROE in this article. Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In other words, it is a profitability ratio which measures the rate of return on the capital provided by the company's shareholders. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. Return on equity can be calculated by using the formula: Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity So, based on the above formula, the ROE for Lovesac is: 6.8% = US$14m ÷ US$201m (Based on the trailing twelve months to May 2025). The 'return' refers to a company's earnings over the last year. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.07. View our latest analysis for Lovesac We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. We now need to evaluate how much profit the company reinvests or "retains" for future growth which then gives us an idea about the growth potential of the company. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics. At first glance, Lovesac's ROE doesn't look very promising. Next, when compared to the average industry ROE of 15%, the company's ROE leaves us feeling even less enthusiastic. As a result, Lovesac reported a very low income growth of 4.0% over the past five years. As a next step, we compared Lovesac's net income growth with the industry and were disappointed to see that the company's growth is lower than the industry average growth of 11% in the same period. The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. Is LOVE fairly valued? This infographic on the company's intrinsic value has everything you need to know. Lovesac doesn't pay any regular dividends, meaning that potentially all of its profits are being reinvested in the business. However, this doesn't explain the low earnings growth the company has seen. So there could be some other explanation in that regard. For instance, the company's business may be deteriorating. Overall, we have mixed feelings about Lovesac. While the company does have a high rate of profit retention, its low rate of return is probably hampering its earnings growth. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. To know more about the latest analysts predictions for the company, check out this visualization of analyst forecasts for the company. — Investing narratives with Fair Values Suncorp's Next Chapter: Insurance-Only and Ready to Grow By Robbo – Community Contributor Fair Value Estimated: A$22.83 · 0.1% Overvalued Thyssenkrupp Nucera Will Achieve Double-Digit Profits by 2030 Boosted by Hydrogen Growth By Chris1 – Community Contributor Fair Value Estimated: €14.40 · 0.3% Overvalued Tesla's Nvidia Moment – The AI & Robotics Inflection Point By BlackGoat – Community Contributor Fair Value Estimated: $359.72 · 0.1% Overvalued View more featured narratives — Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Niu Technologies Provides Second Quarter 2025 Sales Volume Update
BEIJING, July 04, 2025 (GLOBE NEWSWIRE) -- Niu Technologies ('NIU', or 'the Company') (NASDAQ: NIU), the world's leading provider of smart urban mobility solutions, today provided its sales volume results for the second quarter of 2025. 2Q 2025 2Q 2024 1H 2025 1H 2024 China Market 318,719 207,552 501,784 317,667 International Markets 31,371 48,610 51,619 67,634 Total 350,090 256,162 553,403 385,301 In the second quarter of 2025, NIU sold 350,090 units, including e-motorcycles, e-mopeds, e-bicycles, kick-scooters and e-bikes. Sales in the China and international markets were 318,719 and 31,371 units, respectively. In China, we remained focused on our key product line development strategy, enhancing existing models through continuous upgrades and refining our product portfolio. These efforts resulted in an optimized product mix that appeals to a broader range of consumers and delivers a more enjoyable riding experience. During the '618 Shopping Festival,' our high-end models secured top rankings across major e-commerce platforms, including Tmall, JD and Douyin. This strong performance further solidifies NIU's position in China's premium market, appealing to riders who value design and innovation. In the international markets, we launched a comprehensive portfolio of electric motorcycles, including off-road models. Supported by an expanded distribution network, this lineup has significantly strengthened our global market position, despite ongoing challenges in the micromobility sector due to a complex and uncertain environment. Our sales volume count disclosed above is based on the delivery from our manufacturing facility, which may vary slightly from the sales volume measured from a financial accounting and reporting point of view. NIU's sales volume represents only one measure of the company's financial performance and should not be relied upon as an indicator of quarterly financial results, which depend on a variety of factors, including revenues from accessories, spare parts and services, cost of sales, operating expenses, etc. About NIU As the world's leading provider of smart urban mobility solutions, NIU designs, manufactures and sells high-performance electric motorcycles, mopeds, bicycles, as well as kick-scooters and e-bikes. NIU has a diversified product portfolio that caters to the various demands of our users and addresses different urban travel scenarios. Currently, NIU offers two model lineups, comprising a number of different vehicle types. These include (i) the electric motorcycle, moped and bicycle series, including the NQi, MQi, UQi, FQi series and others, and (ii) the micro-mobility series, including the kick-scooter series KQi and the e-bike series BQi. NIU has adopted an omnichannel retail model, integrating the offline and online channels, to sell its products and provide services to users. For more information, please visit Safe Harbor Statement This press release contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will,' 'expects,' 'anticipates,' 'aims,' 'future,' 'intends,' 'plans,' 'believes,' 'estimates,' 'likely to' and similar statements. Among other things, the business outlook and quotations from management in this announcement, as well as NIU's strategic and operational plans, contain forward-looking statements. NIU may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about NIU's beliefs, plans and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: NIU's strategies; NIU's future business development, financial condition and results of operations; NIU's ability to maintain and enhance its 'NIU' brand; its ability to innovate and successfully launch new products and services; its ability to maintain and expand its offline distribution network; its ability to satisfy the mandated safety standards relating to e-scooters; its ability to secure supply of components and raw materials used in e-scooters; its ability to manufacture, launch and sell smart e-scooters meeting customer expectations; its ability to grow collaboration with operation partners; its ability to control costs associated with its operations; general economic and business conditions in China and globally; and assumptions underlying or related to any of the foregoing. Further information regarding these and other risks is included in NIU's filings with the Securities and Exchange Commission. All information provided in this press release is as of the date of this press release, and NIU does not undertake any obligation to update any forward-looking statement, except as required under applicable law. For investor and media inquiries, please contact: Niu TechnologiesE-mail: ir@ in to access your portfolio
